Literature DB >> 15144393

Different low doses of broad-band UVA in the treatment of morphea and systemic sclerosis.

M El-Mofty1, W Mostafa, M El-Darouty, M Bosseila, H Nada, R Yousef, S Esmat, M El-Lawindy, M Assaf, G El-Enani.   

Abstract

BACKGROUND: Numerous treatment modalities, some with potentially hazardous side effects, are currently used for morphea (M) and systemic sclerosis (SS) with limited success. Low-dose ultraviolet A (UVA) phototherapy (20 J/cm(2)) was found to be highly effective for sclerotic patches, even in patients with advanced and rapidly evolving lesions.
OBJECTIVE: To determine the effectiveness of different low doses of UVA in treating patients with M and SS.
METHODS: Sixty-three patients complaining of M and 15 patients complaining of SS received 20 sessions of UVA (320-400 nm) each. Patients were divided randomly into three groups that received 5, 10 and 20 J/cm(2), with cumulative UVA doses of 100, 200, and 400 J/cm(2), respectively. The efficacy of therapy was judged clinically (by sequential inspection and palpation) and histopathologically by morphometry in M cases.
RESULTS: Obvious clinical improvement, with no comparable differences between various low UVA doses, was noted in patients with M and SS, accompanied by histopathological changes towards normalization of collagen.
CONCLUSIONS: After 20 sessions, it appears that lower doses of UVA (5, 10 J/cm(2)) are as beneficial as the relatively higher dose (20 J/cm(2)) in the treatment of M and SS.

Entities:  

Mesh:

Year:  2004        PMID: 15144393     DOI: 10.1111/j.1600-0781.2004.00081.x

Source DB:  PubMed          Journal:  Photodermatol Photoimmunol Photomed        ISSN: 0905-4383            Impact factor:   3.135


  8 in total

1.  Morphea developing at the site of healed herpes zoster.

Authors:  Tae Woo Noh; Sang Hoon Park; Yoo Seok Kang; Un Ha Lee; Hyun Su Park; Sang Jai Jang
Journal:  Ann Dermatol       Date:  2011-05-27       Impact factor: 1.444

2.  Fractional carbon dioxide laser versus low-dose UVA-1 phototherapy for treatment of localized scleroderma: a clinical and immunohistochemical randomized controlled study.

Authors:  S M Shalaby; M Bosseila; M M Fawzy; D M Abdel Halim; S S Sayed; R S H M Allam
Journal:  Lasers Med Sci       Date:  2016-08-10       Impact factor: 3.161

3.  Interventions for morphea.

Authors:  Julia V de Albuquerque; Brenda Ng Andriolo; Monica Ra Vasconcellos; Vinicius T Civile; Anne Lyddiatt; Virginia Fm Trevisani
Journal:  Cochrane Database Syst Rev       Date:  2019-07-16

Review 4.  Updates on morphea: role of vascular injury and advances in treatment.

Authors:  Julio C Sartori-Valinotti; Megha M Tollefson; Ann M Reed
Journal:  Autoimmune Dis       Date:  2013-11-12

Review 5.  Localized scleroderma: clinical spectrum and therapeutic update.

Authors:  Mariana Figueiroa Careta; Ricardo Romiti
Journal:  An Bras Dermatol       Date:  2015 Jan-Feb       Impact factor: 1.896

Review 6.  Morphea and Eosinophilic Fasciitis: An Update.

Authors:  Jorre S Mertens; Marieke M B Seyger; Rogier M Thurlings; Timothy R D J Radstake; Elke M G J de Jong
Journal:  Am J Clin Dermatol       Date:  2017-08       Impact factor: 7.403

Review 7.  Phototherapy in dermatological maladies (Review).

Authors:  Daciana Elena Branisteanu; Diana Stefania Dirzu; Mihaela Paula Toader; Daniel Constantin Branisteanu; Alin Codrut Nicolescu; Ilarie Brihan; Camelia Margareta Bogdanici; George Branisteanu; Andreea Dimitriu; Nicoleta Anton; Elena Andrese Porumb
Journal:  Exp Ther Med       Date:  2022-02-03       Impact factor: 2.447

Review 8.  Phototherapy in Scleroderma.

Authors:  John Hassani; Steven R Feldman
Journal:  Dermatol Ther (Heidelb)       Date:  2016-08-12
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.